Core Insights - Cidara Therapeutics is presenting clinical data on its influenza drug-Fc conjugate candidate, CD388, at the OPTIONS XII conference, highlighting its safety and pharmacokinetic data [1][2] Group 1: Clinical Data Presentations - An oral presentation will summarize safety data from three clinical trials involving 108 subjects, showing no treatment-emergent adverse events related to dose or administration route, supporting further studies for single-dose prevention of seasonal influenza [3] - A poster presentation will cover pharmacokinetics and safety data from 27 healthy Japanese volunteers, indicating low-to-moderate variability in PK parameters and no significant adverse events, supporting further studies in the Japanese population [4] Group 2: Product Overview - CD388 is an investigational drug-Fc conjugate designed to provide universal protection against seasonal and pandemic influenza with a single administration, functioning as a long-acting small molecule inhibitor [5] - The drug is not reliant on an immune response, making it potentially effective for individuals regardless of immune status [5] Group 3: Company Background - Cidara Therapeutics utilizes its Cloudbreak® platform to develop drug-Fc conjugates, with CD388 being the lead candidate aimed at achieving universal prevention of influenza [6] - The company received Fast Track Designation from the FDA for CD388 and plans to advance it into a Phase 2b trial in the 2024 Northern Hemisphere influenza season [6]
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference